4P-Pharma

4P-Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly. Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty. We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

Company Details

Employees
30
Founded
-
Address
1 Rue Du Professeur Calmette, Lille,59000,france
Phone
804 204 071
Email
co****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lille
Looking for a particular 4P-Pharma employee's phone or email?

4p-Pharma Questions

News

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis - BioSpace

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis BioSpace

Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis - Business Wire

Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis Business Wire

Dev4All and Pharmaseed Join Forces in Commercial Cooperation to Boost Preclinical Development Services - Business Wire

Dev4All and Pharmaseed Join Forces in Commercial Cooperation to Boost Preclinical Development Services Business Wire

4Moving Biotech Secures €7.6M France 2030 Grant for Pioneering First-In-Class Disease-Modifying Osteoarthritis Drug - BioSpace

4Moving Biotech Secures €7.6M France 2030 Grant for Pioneering First-In-Class Disease-Modifying Osteoarthritis Drug BioSpace

4P-Pharma Appoints Didier Landais as CEO - CEOWORLD magazine

4P-Pharma Appoints Didier Landais as CEO CEOWORLD magazine

4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing - Business Wire

4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing Business Wire

CSO Kilty replaces Weir as Sitryx CEO - BioCentury

CSO Kilty replaces Weir as Sitryx CEO BioCentury

Chutes & Ladders—Pfizer's Mikael Dolsten steps down as AbbVie's R&D org switches leaders - Fierce Biotech

Chutes & Ladders—Pfizer's Mikael Dolsten steps down as AbbVie's R&D org switches leaders Fierce Biotech

Could GLP-1 RA Drugs Ease Knee OA Pain, Slow Progression? - Medscape

Could GLP-1 RA Drugs Ease Knee OA Pain, Slow Progression? Medscape

Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - globaldata.com

Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update globaldata.com

Jérôme Vailland Joins 4P-Pharma as Chief Financial Officer - Business Wire

Jérôme Vailland Joins 4P-Pharma as Chief Financial Officer Business Wire

[Creative France] Biotech in France - Consulat Général de France à Hong Kong

[Creative France] Biotech in France Consulat Général de France à Hong Kong

CFO Jeff Trigilio leaves Cullinan - BioCentury

CFO Jeff Trigilio leaves Cullinan BioCentury

4P-Pharma Welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as Independent Members of Its Board - Business Wire

4P-Pharma Welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as Independent Members of Its Board Business Wire

4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients - BioSpace

4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients BioSpace

4Moving Biotech welcomes Luc Boblet as Chief Executive Officer to lead next phase of growth - Business Wire

4Moving Biotech welcomes Luc Boblet as Chief Executive Officer to lead next phase of growth Business Wire

4Moving Biotech Completes the Recruitment of Its Phase I Clinical Trial in Patients With Knee Osteoarthritis - Business Wire

4Moving Biotech Completes the Recruitment of Its Phase I Clinical Trial in Patients With Knee Osteoarthritis Business Wire

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant